Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study.

Spry NA, Taaffe DR, England PJ, Judge JS, Stephens DA, Peddle-McIntyre C, Baker MK, Newton RU, Galvão DA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):67-72. doi: 10.1038/pcan.2012.33. Epub 2012 Aug 21.

PMID:
22907511
2.

Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.

Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R.

BJU Int. 2009 Sep;104(6):806-12. doi: 10.1111/j.1464-410X.2009.08458.x. Epub 2009 Mar 5.

3.

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.

BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.

4.

The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.

Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N.

J Urol. 2012 Jun;187(6):2162-6. doi: 10.1016/j.juro.2012.01.080. Epub 2012 Apr 12.

PMID:
22503022
5.

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese.

J Urol. 2002 Jun;167(6):2361-7; discussion 2367.

PMID:
11992038
6.

Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.

Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS.

J Clin Oncol. 2012 May 20;30(15):1864-70. doi: 10.1200/JCO.2011.38.3745. Epub 2012 Apr 9.

7.

Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.

Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU.

J Urol. 2011 Oct;186(4):1291-7. doi: 10.1016/j.juro.2011.05.055. Epub 2011 Aug 17.

PMID:
21849187
8.

Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?

Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM.

Urol Int. 2005;75(3):204-8.

PMID:
16215305
9.
10.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group.

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

12.

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.

Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, Corica T, Korbel E, Weinstein S, McCaul K.

Eur J Cancer. 2006 May;42(8):1083-92. Epub 2006 May 2.

PMID:
16632343
13.

A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.

Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S.

Jpn J Clin Oncol. 2000 Jan;30(1):21-6.

14.

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.

Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M; Chiba Prostate Study Group.

Urology. 2004 Aug;64(2):341-5.

PMID:
15302491
15.

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group.

J Urol. 2001 Aug;166(2):500-6; discussion 506-7.

PMID:
11458055
16.
18.

Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.

Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F.

Urol Int. 1998;60 Suppl 1:9-16; discussion 16-7.

PMID:
9563139
19.
20.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.

BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.

Items per page

Supplemental Content

Write to the Help Desk